Analysts Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Target Price at $39.25

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have received an average rating of “Moderate Buy” from the ten analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $39.25.

Several brokerages recently commented on GMAB. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. HC Wainwright reduced their price target on shares of Genmab A/S from $41.00 to $39.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Wall Street Zen raised shares of Genmab A/S from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Finally, Truist Financial reissued a “buy” rating and set a $48.00 price objective (down previously from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th.

Genmab A/S Stock Performance

Shares of GMAB opened at $33.47 on Friday. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $35.43. The stock’s 50-day simple moving average is $32.23 and its 200 day simple moving average is $28.82. The stock has a market capitalization of $21.50 billion, a price-to-earnings ratio of 14.24, a price-to-earnings-growth ratio of 19.08 and a beta of 0.90.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, November 6th. The company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.17. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $975.40 million. On average, research analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC purchased a new stake in Genmab A/S in the second quarter valued at approximately $257,000. Park Avenue Securities LLC increased its stake in Genmab A/S by 5.9% in the second quarter. Park Avenue Securities LLC now owns 14,940 shares of the company’s stock valued at $309,000 after acquiring an additional 832 shares during the last quarter. Eagle Global Advisors LLC raised its position in Genmab A/S by 0.5% during the second quarter. Eagle Global Advisors LLC now owns 210,295 shares of the company’s stock valued at $4,345,000 after purchasing an additional 1,000 shares in the last quarter. DAVENPORT & Co LLC lifted its stake in Genmab A/S by 6.8% during the second quarter. DAVENPORT & Co LLC now owns 33,826 shares of the company’s stock worth $699,000 after purchasing an additional 2,147 shares during the last quarter. Finally, Callan Family Office LLC purchased a new position in shares of Genmab A/S in the 2nd quarter worth about $655,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.